Role of L-type calcium channel blocking in epidermal growth factor receptor-independent activation of extracellular signal regulated kinase 1/2

Journal of Hypertension

Volumn 23, Issue 2, 2005, Pages 337-350

  Yin, Xing ^a   Polidano, Evelyne ^a   Faverdin, Claude ^a   Marche, Pierre ^a,b  

^a CNRS   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Akt; Amlodipine; Angiotensin II; BAPTA; Calcium; Epidermal growth factor receptor; Isradipine; Mitogen activated protein kinases; Thrombin; Vascular smooth muscle cell; Verapamil

Indexed keywords

AMLODIPINE; ANGIOTENSIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; G PROTEIN COUPLED RECEPTOR; ISRADIPINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; THROMBIN; VERAPAMIL;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CANCER PATIENT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 14044275116     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200502000-00016     Document Type: Article

References (55)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 382:801-809.
2. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Hypertension 1993; 21:391-397.
3. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl Med 1994; 330:1431-1438.
4. Whitmarsh AJ, Davis RJ. A central control for cell growth. Nature 2000; 403:255-256.
5. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-1657.
6. Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001; 276:33630-33637.
7. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286:1738-1741.
8. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002; 277:31099-31106.
9. q-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. J Biol Chem 1997; 272:19125-19132.
10. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann NY Acad Sci 2001; 947:42-54.
11. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein- coupled receptors. Nature 1996; 379:557-560.
12. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884-888.
13. 2+ pool content is linked to control of cell growth. Proc Natl Acad Sci USA 1993; 90:4986-4990.
14. Mogami H, Kojima I. Stimulation of calcium entry is a prerequisite for DNA synthesis induced by platelet-derived growth factor in vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 196:650-658.
15. Bobe R, Yin X, Roussanne MC, Stepien O, Polidano E, Faverdin C, Marche P. Evidence for ERK1/2 activation by thrombin that is independent of EGFR transactivation. Am J Physiol Heart Circ Physiol 2003; 285:H745-H754.
16. Hughes AD. Calcium channels in vascular smooth muscle cells. J Vasc Res 1995; 32:353-370.
17. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension 1992; 20:713-736.
18. 2+-channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. Proc Natl Acad Sci USA 1989; 86:2388-2392.
19. 2+ transients and cell cycle progression in vascular smooth muscle cells. Eur J Pharmacol 1998; 344:323-331.
20. 2+ stores in thrombin-stimulated vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 279:H1220-H1227.
21. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996; 271:27456-27461.
22. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971; 50:172-186.
23. Hérembert T, Gogusev J, Zhu DL, Drueke TB, Marche P. Control of vascular smooth muscle cell growth by macrophage-colony stimulating factor. Biochem J 1997; 325:123-128.
24. Graf K, Xi XP, Yang D, Reck E, Hsueh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997; 29:334-339.
25. Lin C, Shyr M, Chien C, Wang C, Chiu C, Hsiao L, Yang C. Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells. Cell Signal 2001; 13:257-267.
26. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-242.
27. Saito Y, Berk BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 2001; 33: 3-7.
28. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 1998; 273:8890-8896.
29. + enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39:208-214.
30. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists. Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23:2155-2163.
31. 2+ signaling in preglomerular arteriolar smooth muscle cells of genetically hypertensive rats. Am J Physiol Renal Physiol 1999; 276:F260-F270.
32. Stepien O, Zhang Y, Zhu D, Marche P. Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J Hypertens 2002; 20:95-102.
33. 2+ channels involved in endothelin-1-induced mitogenic responses in vascular smooth muscle cells. Eur J Pharmacol 2001; 422:15-21.
34. Purdy KE, Arendshorst WJ. Iloprost inhibits inositol-1,4,5-trisphosphate- mediated calcium mobilization stimulated by angiotensin II in cultured preglomerular vascular smooth muscle cells. J Am Soc Nephrol 2001; 12:19-28.
35. Touyz RM, Schiffrin EL. Role of calcium influx and intracellular calcium stores in angiotensin II-mediated calcium hyper-responsiveness in smooth muscle from spontaneously hypertensive rats. J Hypertension 1997; 15:1431-1439.
36. Kruse HJ, Bauriedel G, Heimerl J, Höfling B, Weber PC. Role of L-type calcium channels on stimulated calcium influx and on proliferative activity of human coronary smooth muscle cells. J Cardiovasc Pharmacol 1994; 24:328-335.
37. Walker TR, Moore SM, Lawson MF, Panettieri RA Jr, Chilvers ER. Platelet-derived growth factor-BB and thrombin activate phosphoinositide 3-kinase and protein kinase B. Role in mediating airway smooth muscle proliferation. Mol Pharmacol 1998; 54:1007-1015.
38. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, Krymskaya VP. PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002; 283:L354-L363.
39. Lin CC, Shyr MH, Chien CS, Wang CC, Chiu CT, Hsiao LD, Yang CM. Thrombin-stimulated cell proliferation mediated through activation of Ras/ Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells. Cell Signal 2002; 14:265-275.
40. Reynolds CM, Eguchi S, Frank GD, Motley ED. Signaling mechanisms of heparin-binding epidermal growth factor-like growth factor in vascular smooth muscle cells. Hypertension 2002; 39:525-529.
41. Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ. Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem 1996; 271:12133-12136.
42. Wennstrom S, Downward J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 1999; 19:4279-4288.
43. 2+/calmodulin-sensitive tyrosine kinase. J Biol Chem 1996; 271:14169-14175.
44. El Mabrouk M, Touyz RM, Schiffrin EL. Differential ANG II-induced growth activation pathways in mesenteric artery smooth muscle cells from SHR. Am J Physiol Heart Circ Physiol 2001; 281:H30-H39.
45. Silfani TN, Freeman EJ. Phosphatidylinositide 3-kinase regulates angiotensin II-induced cytosolic phospholipase A2 activity and growth in vascular smooth muscle cells. Arch Biochem Biophys 2002; 402: 84-93.
46. Harp JB, Sayeski PP, Scanlon M, Bernstein KE, Marrero MB. Role of intracellular calcium in the angiotensin II-mediated tyrosine phosphorylation and dephosphorylation of PLC-γ1. Biochem Biophys Res Commun 1997; 232:540-544.
47. Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle - Role of tyrosine kinases. Circ Res 1997; 80:607-616.
48. Courtneidge SA. Role of Src in signal transduction pathways. Biochem Soc Trans 2002; 30:11-17.
49. Rosen LB, Greenberg ME. Stimulation of growth factor receptor signal transduction by activation of voltage-sensitive calcium channels. Proc Natl Acad Sci USA 1996; 93:113-118.
50. Mulvaney JM, Zhang T, Fewtrell C, Roberson MS. Calcium influx through L-type channels is required for selective activation of extracellular signal-regulated kinase by gonadotropin-releasing hormone. J Biol Chem 1999; 274:29796-29804.
51. Mancini GBJ. Antiatherosclerotic effects of calcium channel blockers. Prog Cardiovasc Dis 2002; 45:1-20.
52. Salomone S, Morel N, Godfraind T. A therapeutic dosage of amlodipine prevents vascular hyporeactivity induced in rats by lipopolysaccharide. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:252-259.
53. Nayler WG. Amlodipine: An overview. Clin Drug Invest 1997; 13(suppl): 1-11.
54. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95:851-867.
55. Mendelsohn J, Basetga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799.